| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/31/2013 | US20130028910 Hmg1 antibody for treating inflammatory conditions |
| 01/31/2013 | US20130028909 Depletion of Teratoma-Forming Pluripotent Stem Cells |
| 01/31/2013 | US20130028908 MONOCLONAL ANTIBODIES DIRECTED AGAINST HIV p17 PROTEIN |
| 01/31/2013 | US20130028905 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028904 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028901 Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| 01/31/2013 | US20130028900 Methods and compositions for the generation and use of conformation-specific antibodies |
| 01/31/2013 | US20130028894 Methods of treating il-tif associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors |
| 01/31/2013 | US20130028893 Therapeutic antibodies with reduced side effect |
| 01/31/2013 | US20130028888 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 01/31/2013 | US20130028862 Treatment with anti-vegf antibodies |
| 01/31/2013 | US20130028835 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses |
| 01/31/2013 | CA2842860A1 Sur-binding proteins |
| 01/31/2013 | CA2842649A1 Multivalent antigen-binding fv molecule |
| 01/31/2013 | CA2842099A1 Antigen binding constructs |
| 01/31/2013 | CA2841588A1 Stabilized formulations containing anti-pcsk9 antibodies |
| 01/31/2013 | CA2841185A1 Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
| 01/31/2013 | CA2840018A1 Variants of humanized immunomodulatory monoclonal antibodies |
| 01/30/2013 | EP2551347A1 Pharmaceutical composition for preventing or treating cancer |
| 01/30/2013 | EP2551282A2 Antibodies against CD38 for treatment of multiple myeloma |
| 01/30/2013 | EP2550975A1 Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| 01/30/2013 | EP2550363A1 Adam6 mice |
| 01/30/2013 | EP2550361A1 Compositions and methods for treating neurological disorders |
| 01/30/2013 | EP2550297A1 Disulfide stabilized dvd-lg molecules |
| 01/30/2013 | EP2550296A1 Monoclonal antibodies for treatment of cancer |
| 01/30/2013 | EP2550295A1 Anti-lrp6 antibodies |
| 01/30/2013 | EP2550294A2 Prophylaxis of colorectal and gastrointestinal cancer |
| 01/30/2013 | EP2550019A2 Temperature sensitive conjugate compositions, and uses related thereto |
| 01/30/2013 | EP2550017A2 Disulfide stabilised antibodies and fragments thereof |
| 01/30/2013 | EP2550009A1 Dendritic cell inhibitory proteins from ticks |
| 01/30/2013 | CN1835968B Compositions and methods for increasing bone mineralization |
| 01/30/2013 | CN102906118A Biological materials related to HER3 |
| 01/30/2013 | CN102906117A Anti-LRP6 antibodies |
| 01/30/2013 | CN102906116A 融合蛋白 The fusion protein |
| 01/30/2013 | CN102906115A Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| 01/30/2013 | CN102906114A Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
| 01/30/2013 | CN102906113A Therapeutic dll4 binding proteins |
| 01/30/2013 | CN102906112A Trail R2-Specific Multimeric Scaffolds |
| 01/30/2013 | CN102906111A Human antibodies specifically binding to the hepatitis B virus surface antigen |
| 01/30/2013 | CN102905727A IL-17A antagonists |
| 01/30/2013 | CN102905723A Anti-FGFR2 antibodies |
| 01/30/2013 | CN102898525A Recombination antihuman CD4 chimeric antibody |
| 01/30/2013 | CN102898524A Human-mouse chimeric antibody of anti-human tumor necrosis factor related apoptosis-inducing ligand receptor DR5, preparation method and uses thereof |
| 01/30/2013 | CN102898523A N-substituted-tetrahydropyridylindole-monoclonal antibody CD14 conjugates, and preparation method and application thereof |
| 01/30/2013 | CN102898522A Tetrahydropyridinopyran-monoclonal antibody CD14 conjugate with anti-tumor activity and preparation method and use thereof |
| 01/30/2013 | CN102898521A Anti-beta-interferon monoclonal antibody and its application |
| 01/30/2013 | CN102898520A Anti-CTNNB1 monoclonal antibody 3F9 and application thereof |
| 01/30/2013 | CN102898519A Monoclonal antibodies against amyloid beta protein and uses thereof |
| 01/30/2013 | CN102898518A Preparation method for special anti-bovine mastitis pathogenic microorganism IgY |
| 01/30/2013 | CN102898517A Anti-West Nile virus non-structural protein 1 antibodies and application thereof |
| 01/30/2013 | CN102895663A Compositions containing EGFL 7 antagonist for modulating vascular development and methods |
| 01/30/2013 | CN102250910B Human soluble B7-DC quantitative detection kit |
| 01/30/2013 | CN101538329B Variable region sequence for novel anti-beta amyloid polypeptide antibody and coding sequence thereof |
| 01/30/2013 | CN101415811B Humanized monoclonal antibodies to hepatocyte growth factor |
| 01/30/2013 | CN101397342B Anti-schistosoma japonicum monoclonal antibody NP11-4 chimeric Fab antibody, preparation method and use |
| 01/30/2013 | CN101357944B Anti-idio-typic antibody NP30 chimeric Fab fragment of japonicum, preparation method and application |
| 01/30/2013 | CN101258166B Antibody combining with STEAP-1 protein and deriving molecule thereof |
| 01/29/2013 | US8362216 Method of detection using antibodies that specifically bind hedgehog-derived polypeptides |
| 01/29/2013 | US8362215 Antibodies immunoreactive with heregulin-coupled HER3 |
| 01/29/2013 | US8362214 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| 01/29/2013 | US8362213 Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| 01/29/2013 | US8362212 monoclonal antibody, or antigen binding fragment thereof that binds to human IL-23p19 at an epitope comprising residues 133-140 of SEQ ID NO: 29; treatment of inflammatory, autoimmune, and proliferative disorders |
| 01/29/2013 | US8362211 Anti-CD38 antibodies |
| 01/29/2013 | US8362210 Antibody variants with enhanced complement activity |
| 01/29/2013 | US8362209 Telomerase reverse transcriptase variant |
| 01/29/2013 | US8362208 Immunoglobulins |
| 01/29/2013 | US8361969 Designer cyclic peptides—HIV gp120 antagonists and their applications |
| 01/29/2013 | US8361751 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| 01/29/2013 | US8361740 Peptide standards |
| 01/29/2013 | US8361729 Detection of cells expressing T1R2 taste receptor |
| 01/29/2013 | US8361479 Promiscuous PAP CD4 T cell epitopes |
| 01/29/2013 | US8361472 Anti-PSGL-1 antibodies |
| 01/29/2013 | US8361468 Humanized anti-C5aR antibodies |
| 01/29/2013 | US8361466 Tweak receptor |
| 01/29/2013 | US8361465 Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| 01/29/2013 | US8361463 Humanized antibodies against human interferon-alpha |
| 01/29/2013 | US8361462 Anti-apoptotic protein antibodies |
| 01/29/2013 | US8361461 Anti-IGF-IR antibodies and uses thereof |
| 01/29/2013 | US8361460 Food allergens, method of detecting food allergens and method of detecting food allergy-inducing foods |
| 01/29/2013 | CA2677781C Nitrilases |
| 01/29/2013 | CA2522645C New monoclonal antibody capable of binding integrin alpha10beta1 |
| 01/29/2013 | CA2505342C Bispecific antibody molecule |
| 01/29/2013 | CA2501756C Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage |
| 01/29/2013 | CA2431891C Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 01/29/2013 | CA2416137C Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 01/29/2013 | CA2325574C Porcine adenovirus type 3 genome |
| 01/29/2013 | CA2308623C Method of making monoclonal antibodies using polymorphic transgenic animals |
| 01/27/2013 | CA2783757A1 Mixed mode ligands |
| 01/24/2013 | WO2013013075A2 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| 01/24/2013 | WO2013013029A1 Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes |
| 01/24/2013 | WO2013012866A1 Methods and compositions for inhibiting polyomavirus-associated pathology |
| 01/24/2013 | WO2013012855A1 Apelin antigen-binding proteins and uses thereof |
| 01/24/2013 | WO2013012733A1 Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| 01/24/2013 | WO2013012722A1 Anti-folate receptor alpha antibodies and uses thereof |
| 01/24/2013 | WO2013012648A1 Gdf15 in diagnostic and therapeutic applications |
| 01/24/2013 | WO2013012022A1 Stable protein-containing preparation containing argininamide or analogous compound thereof |
| 01/24/2013 | WO2013011431A1 A topical composition for the treatment of alopecia |
| 01/24/2013 | WO2013011407A1 Interleukin-31 monoclonal antibody |
| 01/24/2013 | WO2013011347A1 Neutralizing anti-influenza a virus antibodies and uses thereof |
| 01/24/2013 | WO2013011076A2 Antigen-binding proteins with increased fcrn binding |